Epizyme to Participate in Oppenheimer & Co. 28th Annual Healthcare Conference

CAMBRIDGE, Mass., March 12, 2018 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the Oppenheimer & Co. 28th Annual Healthcare Conference at 10:20 a.m. ET on March 20, 2018 in New York City.

To access the live webcast of Epizyme’s presentation, please visit the Events & Presentations page within the Investor section of the company’s website at www.epizyme.com. A replay of the webcast will be available on the Epizyme website for 60 days following the event.

About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program and its next development candidate, EZM8266, is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.

Contacts

Media:
Cheya Pope, Epizyme, Inc.
[email protected]
(617) 229-7561

Investors:
Jason Fredette, Epizyme, Inc.  
[email protected]  
(617) 500-0623